Vanguard Personalized Indexing Management LLC Acquires Shares of 2,387 Verona Pharma PLC American Depositary Share $VRNA

Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 2,387 shares of the company’s stock, valued at approximately $226,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. IFP Advisors Inc bought a new position in shares of Verona Pharma PLC American Depositary Share during the second quarter valued at approximately $52,000. Geneos Wealth Management Inc. grew its holdings in shares of Verona Pharma PLC American Depositary Share by 44.2% during the first quarter. Geneos Wealth Management Inc. now owns 630 shares of the company’s stock valued at $40,000 after purchasing an additional 193 shares during the last quarter. Acadian Asset Management LLC bought a new position in shares of Verona Pharma PLC American Depositary Share during the first quarter valued at approximately $48,000. NewEdge Advisors LLC bought a new position in shares of Verona Pharma PLC American Depositary Share during the first quarter valued at approximately $58,000. Finally, Farther Finance Advisors LLC bought a new position in shares of Verona Pharma PLC American Depositary Share during the second quarter valued at approximately $95,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

Verona Pharma PLC American Depositary Share Price Performance

Shares of NASDAQ:VRNA opened at $106.91 on Friday. The company has a current ratio of 10.71, a quick ratio of 10.54 and a debt-to-equity ratio of 0.87. Verona Pharma PLC American Depositary Share has a 1 year low of $31.09 and a 1 year high of $106.93. The business has a fifty day simple moving average of $106.41 and a 200 day simple moving average of $92.62. The firm has a market cap of $9.21 billion, a price-to-earnings ratio of -107.99 and a beta of 0.05.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.14. Verona Pharma PLC American Depositary Share had a negative return on equity of 21.12% and a negative net margin of 36.62%.The business had revenue of $103.14 million during the quarter, compared to analyst estimates of $90.41 million. As a group, sell-side analysts predict that Verona Pharma PLC American Depositary Share will post -1.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. TD Cowen lowered Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 9th. Cowen downgraded Verona Pharma PLC American Depositary Share from a “buy” rating to a “hold” rating in a research report on Wednesday, July 9th. Zacks Research upgraded Verona Pharma PLC American Depositary Share to a “hold” rating in a research report on Friday, August 8th. Canaccord Genuity Group downgraded Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating and set a $107.00 price objective for the company. in a research report on Wednesday, July 9th. Finally, Roth Capital downgraded Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 10th. Two equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $109.00.

Insider Buying and Selling at Verona Pharma PLC American Depositary Share

In other Verona Pharma PLC American Depositary Share news, Director Martin Edwards sold 10,808 shares of the business’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $13.14, for a total transaction of $142,017.12. Following the completion of the transaction, the director owned 157,992 shares of the company’s stock, valued at $2,076,014.88. The trade was a 6.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Mark W. Hahn sold 208,912 shares of Verona Pharma PLC American Depositary Share stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $13.14, for a total value of $2,745,103.68. Following the completion of the transaction, the chief financial officer owned 12,464,968 shares in the company, valued at $163,789,679.52. The trade was a 1.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 540,584 shares of company stock worth $7,103,274 in the last 90 days. Company insiders own 4.80% of the company’s stock.

Verona Pharma PLC American Depositary Share Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.